PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations-Reference-Cited by-同舟云学术

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

Author:

Zou Weiping¹,Wolchok Jedd D.²,Chen Lieping³

Affiliation:

1. Department of Surgery, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA.

2. Department of Medicine and the Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

3. Department of Immunobiology, Yale University School of Medicine, New Haven CT 06519, USA.

Abstract

PD pathway blockade elicits durable antitumor responses in a subset of patients with a broad spectrum of cancers.

Funder

U.S. NIH

Ludwig Trust

Lloyd Charitable Trust

CRI/SU2C Immunotherapy Dream Team

Ovarian Cancer Research Fund

U.S. Department of Defense

Stand Up to Cancer

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference177 articles.

Cited by 1892 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Mechanisms of resistance to immunotherapy;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025